| Name | Title | Contact Details |
|---|
IQUW is a global specialty (re) insurer at Lloyds (syndicate 1856), underwriting complex risks and developing a new way to combine data, intelligent automation and human expertise to make smart decisions, fast. Led by a team of expert underwriters, we underwrite a diverse, multi-line product portfolio including Cargo, Cyber, Delegated Authority Property, D&F Property, D&O, Energy, Financial Institutions, Marine and Energy Liability, Political Violence, Terrorism and War, Property Treaty and Specialty Reinsurance. And because we are a Lloyds syndicate, all our policies come with an A+ rating from Lloyds. To connect with a member of the IQUW team, visit IQUW.com or to visit, you can find us at our HQ in 30 Fenchurch Street, London or at Box 64, 137 and 221 at Lloyds.
At Diversity Matters, we support businesses that encourage diversity. With our consulting services we aim to help businesses understand the power of inclusion. Whether youre just starting to embrace diversity in your organization or looking to strengthen existing initiatives, Diversity Matters can help.
The Denver Public Library (DPL) is a public library system serving the city of Denver, Colorado. Established in 1889, it has grown into a vital community resource with 27 locations throughout the city. The library offers a wide range of services, including early literacy programs for children, digital access with computer training, and various community programs such as workshops and cultural events. DPL provides access to a vast collection of materials, including books, audiobooks, e-books, and DVDs. It also offers digital resources like databases and online courses. The library features special collections, including the Western History and Genealogy Department and the Blair-Caldwell African American Research Library. Its mission is to create welcoming spaces for exploration and connection, emphasizing values such as curiosity, equity, and community engagement.
In 2015, an important group of investors alongside a group of experienced professionals in the Reinsurance industry, acquired a majority interest in MBI Americas. Now, XS Global, a well-known regional MGA and Coverholder at Lloyds. The groups footprint and ambitions now encompass the underwriting space, utilizing strong synergies that exist between the groups core business strategy. Our unique structure provides us opportunities to deploy targeted reinsurance capacity both directly to corporates and to retail brokers via expert and locally based underwriters. We are proud to say we invest in talent and our team has proven skills, excellent access, and a proven track record for underwriting profitable business in the Latin America region and beyond.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.